Tra­vere Ther­a­peu­tics just miss­es on con­fir­ma­to­ry study for kid­ney dis­ease drug, stock plum­mets

Tra­vere Ther­a­peu­tics’ kid­ney dis­ease drug nar­row­ly failed its con­fir­ma­to­ry study sev­en months af­ter it won ac­cel­er­at­ed ap­proval.

Tra­vere said Thurs­day it still in­tends to ap­ply …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER